Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting

American Journal of Physiology - Endocrinology and Metabolism

Volumn 289, Issue 3 52-3, 2005, Pages

  Esposito, John G ^a   Thomas, Scott G ^a,b   Kingdon, Lori ^d   Ezzat, Shereen ^c,d  

^a Faculty of Medicine   (Canada)

^b Faculty of Physical Education and Health   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Endocrine; Exercise; Fatigue; Human growth hormone; Human immunodeficiency virus wasting syndrome; Physical fitness

Indexed keywords

ANABOLIC AGENT; GROWTH HORMONE;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOCRINE FUNCTION; EXERCISE TEST; FATIGUE; HIGH RISK PATIENT; HORMONE ACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEASUREMENT; MUSCLE ATROPHY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WASTING SYNDROME; WEIGHT REDUCTION;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; BODY COMPOSITION; ENERGY METABOLISM; EXERCISE; EXERTION; FATIGUE; HIV WASTING SYNDROME; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LINEAR MODELS; MALE; MIDDLE AGED; MOTOR ACTIVITY;

EID: 23944463887     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00013.2005     Document Type: Article

References (65)

1. American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. Philadelphia, PA: Lippincott Williams & Wilkins, 2000.
2. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166: 111-117, 2002.
3. ATS/ACCP. Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167: 211-277, 2003.
4. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92: 212-218, 1995.
5. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296-302, 1996.
6. Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, and Klibanski A. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125: 883-890, 1996.
7. Beaver WL, Wasserman K, and Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 60: 2020-2027, 1986.
8. Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L, and Isaksson OG. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 76: 309-317, 1993.
9. Beniamini Y, Rubenstein JJ, Zaichkowsky LD, and Crim MC. Effects of high-intensity strength training on quality-of-life parameters in cardiac rehabilitation patients. Am J Cardiol 80: 841-846, 1997.
10. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, Kronenberg MW, Kostis JB, Kohn RM, Guillotte M, Greenberg B, Woods PA, and Bourassa MG. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA 270: 1702-1707, 1993.
11. Brubaker PH, Marburger CT, Morgan TM, Fray B, and Kitzman DW. Exercise responses of elderly patients with diastolic versus systolic heart failure. Med Sci Sports Exerc 35: 1477-1485, 2003.
12. Butland RJ, Pang J, Gross ER, Woodcock AA, and Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J 284: 1607-1608, 1982.
13. Cade WT, Peralta L, and Keyser RE. Aerobic capacity in late adolescents infected with HIV and controls. Pediatr Rehabil 5: 161-169, 2002.
14. Cahalin LP, Mathier MA, Semigran MJ, Dec GW, and DiSalvo TG. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest 110: 325-332, 1996.
15. Caiozzo VJ, Davis JA, Ellis JF, Azus JL, Vandagriff R, Prietto CA, and McMaster WC. A comparison of gas exchange indices used to detect the anaerobic threshold. J Appl Physiol 53: 1184-1189, 1982.
16. Canadian Physical Activity, Fitness & Lifestyle Appraisal, The. C.S.E.P.'s Plan for Healthy Active Living. Ottawa, ON, Canada: Health Canada, 1998.
17. Chuang ML, Lin IF, and Wasserman K. The body weight-walking distance product as related to lung function, anaerobic threshold and peak VO2 in COPD patients. Respir Med 95: 618-626, 2001.
18. Davis JA, Storer TW, and Caiozzo VJ. Prediction of normal values for lactate threshold estimated by gas exchange in men and women. Eur J Appl Physiol 76: 157-164, 1997.
19. Enright PL and Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158: 1384-1387, 1998.
20. Esposito JG, Thomas SG, Kingdon L, and Ezzat S. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. J Clin Endocrinol Metab 89: 5124-5131, 2004.
21. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB, Marwick TH, McCallister BD, Thompson PD Jr, Winters WL, Yanowitz FG, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Lewis RP, O'Rourke RA, and Ryan TJ. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 30: 260-311, 1997.
22. Gibson SJ. The measurement of mood states in older adults. J Gerontol B Psychol Sci Soc Sci 52: P167-P174, 1997.
23. Gore DC, Honeycutt D, Jahoor F, Wolfe RR, and Herndon DN. Effect of exogenous growth hormone on whole-body and isolated-limb protein kinetics in burned patients. Arch Surg 126: 38-43, 1991.
24. Grinspoon S, Corcoran C, Rosenthal D, Stanley T, Parlman K, Costello M, Treat M, Davis S, Burrows B, Basgoz N, and Klibanski A. Quantitative assessment of cross-sectional muscle area, functional status, and muscle strength in men with the acquired immunodeficiency syndrome wasting syndrome. J Clin Endocrinol Metab 84: 201-206, 1999.
25. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics 21: 467-480, 1965.
26. Guyatt GH, Thompson PJ, Berman LB, Sullivan MJ, Townsend M, Jones NL, and Pugsley SO. How should we measure function in patients with chronic heart and lung disease? J Chronic Dis 38: 517-524, 1985.
27. He Q, Engelson ES, Albu JB, Heymsfield SB, and Kotler DP. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J Appl Physiol 94: 2051-2057, 2003.
28. Hendrican MC, McKelvie RS, Smith T, McCartney N, Pogue J, Teo KK, and Yusuf S. Functional capacity in patients with congestive heart failure. J Card Fail 6: 214-219, 2000.
29. Hinderliter AL, Willis PWt Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Koch G, Li S, Clayton LM, Jobsis MM, Blackburn SD Jr, Crow JW, and Long WA. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation 95: 1479-1486, 1997.
30. Hunt SM, McEwen J, and McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. JR Coll Gen Pract 35: 185-188, 1985.
31. Johnson JE, Anders GT, Blanton HM, Hawkes CE, Bush BA, McAllister CK, and Matthews JI. Exercise dysfunction in patients seropositive for the human immunodeficiency virus. Am Rev Respir Dis 141: 618-622. 1990.
32. Keyser RE, Peralta L, Cade WT, Miller S, and Anixt J. Functional aerobic impairment in adolescents seropositive for HIV: a quasiexperimental analysis. Arch Phys Med Rehabil 81: 1479-1484, 2000.
33. Lane RJ, Woodrow D, and Archard LC. Lactate responses to exercise in chronic fatigue syndrome. J Neurol Neurosurg Psychiatry 57: 662-663, 1994.
34. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, and Schambelan M. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 86: 3480-3487, 2001.
35. Lohman TG, Roche AF, and Martorell R. Anthropometric Standardization Reference Manual. Champaign: Human Kinetics Books, 1988.
36. MacArthur RD, Levine SD, and Birk TJ. Supervised exercise training improves cardiopulmonary fitness in HIV-infected persons. Med Sci Sports Exerc 25: 684-688, 1993.
37. McNair D and Lorr L. Profile of Mood States Manual. San Diego, CA: Educational & Industrial Testing Service, 1971.
38. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, and Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161: 487-492, 2000.
39. Moyle GJ, Daar ES, Gertner JM, Kotler DP, Melchior JC, O'Brien F, and Svanberg E. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretrovirai therapy. J Acquir Immune Defic Syndr Hum Retrovirol 35: 367-375, 2004.
40. Myers J and Ashley E. Dangerous curves. A perspective on exercise, lactate, and the anaerobic threshold. Chest 111: 787-795, 1997.
41. Nass R, Huber RM, Klauss V, Muller OA, Schopohl J, and Strasburger CJ. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 80: 552-557, 1995.
42. Nyenhuis DL, Yamamoto C, Luchetta T, Terrien A, and Parmentier A. Adult and geriatric normative data and validation of the profile of mood states. J Clin Psychol 55: 79-86, 1999.
43. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, and Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860, 1998.
44. Palenicek JP, Graham NM, He YD, Hoover DA, Oishi JS, Kingsley L, and Saah AJ. Weight loss prior to clinical AIDS as a predictor of survival. Multicenter AIDS Cohort Study Investigators. J Acquir Immune Defic Syndr Hum Retrovirol 10: 366-373, 1995.
45. Patessio A, Casaburi R, Carone M, Appendini L, Donner CF, and Wasserman K. Comparison of gas exchange, lactate, and lactic acidosis thresholds in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 148: 622-626, 1993.
46. Perna FM, LaPerriere A, Klimas N, Ironson G, Perry A, Pavone J, Goldstein A, Majors P, Makemson D, Talutto C, Schneiderman N, Fletcher MA, Meijer OG, and Koppes L. Cardiopulmonary and CD4 cell changes in response to exercise training in early symptomatic HIV infection. Med Sci Sports Exerc 31: 973-979, 1999.
47. Pothoff G, Wassermann K, and Ostmann H. Impairment of exercise capacity in various groups of HIV-infected patients. Respiration 61: 80-85, 1994.
48. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, and Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353, 2004.
49. Rodriguez-Arnao J, Jabbar A, Fulcher K, Besser GM, and Ross RJ. Effects of growth hormone replacement on physical performance and body composition in GH deficient adults. Clin Endocrinol (Oxf) 51: 53-60, 1999.
50. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozzette SA, and Breitmeyer JB. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial Serostim Study Group. Ann Intern Med 125: 873-882, 1996.
51. Solway S, Brooks D, Lacasse Y, and Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 119: 256-270, 2001.
52. Stringer WW. Mechanisms of exercise limitation in HIV+ individuals. Med Sci Sports Exerc 32: S412-S421, 2000.
53. Stringer WW, Berezovskaya M, O'Brien WA, Beck CK, and Casaburi R. The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients. Med Sci Sports Exerc 30: 11-16, 1998.
54. Sueta CA, Gheorghiade M, Adams KF Jr, Bourge RC, Murali S, Uretsky BF, Pritzker MR, McGoon MD, Butman SM, Grossman SH, Crow JW, Shaffer CL, and Thorn MD. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. Am J Cardiol 75: 34A-43A, 1995.
55. Suttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, and Muller MJ. Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr Hum Retrovirol 8: 239-246, 1995.
56. Tainai M, Kubota M, Ikeda M, Nagao K, Irikura N, Sugiyama M, Yoshikawa H, Kawamori R, and Kamada T. Usefulness of anaerobic threshold for evaluating daily life activity and prescribing exercise to the healthy subjects and patients. J Med Syst 17: 219-225, 1993.
57. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, and Gorbach SL. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 31: 230-236, 2002.
58. Thiebaut R, Malvy D, Marimoutou C, and Davis F. Anthropometric indices as predictors of survival in AIDS adults. Aquitaine Cohort, France, 1985-1997 Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Eur J Epidemiol 16: 633-639, 2000.
59. Thomas SG, Esposito JG, and Ezzat S. Exercise training benefits growth hormone (GH)-deficient adults in the absence or presence of GH treatment. J Clin Endocrinol Metab 88: 5734-5738, 2003.
60. Thomas SG, Woodhouse LJ, Pagura SM, and Ezzat S. Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. Clin Endocrinol (Oxf) 56: 351-358, 2002.
61. Vance ML and Mauras N. Growth hormone therapy in adults and children. N Engl J Med 341: 1206-1216, 1999.
62. Wanke C, Gerrior J, Kantaros J, Coakley E, and Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13: 2099-2103, 1999.
63. Wasserman K, Hansen JE, Sue DY, Casaburi R, and Whipp BJ. Principles of Exercise Testing and Interpretation: Including Pathophysiology and Clinical Applications, Philadelphia, PA: Lippincott Williams & Wilkins, 1999.
64. Wheeler DA, Gibert CL, Launer CA, Muurahainen N, Elion RA, Abrams DI, and Bartsch GE. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 18: 80-85, 1998.
65. Woodhouse LJ, Asa SL, Thomas SG, and Ezzat S. Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 84: 4570-4577, 1999.